Fig. 6

hnRNPL-LINC02273 promotes breast cancer metastasis through AGR2. a Relative mRNA and protein level of AGR2 after hnRNPL knockdown in MDA-MB-231 cells (two clones named gRNA32 and gRNA38) assayed by RT-qPCR and immunoblotting. Normalized to GAPDH. n = 3, biological replicates. b AGR2 mRNA and protein expression level in WT and LINC02273 KO MDA-MB-231 cells with or without hnRNPL overexpression assayed by RT-qPCR (normalized to GAPDH) and immunoblotting. n = 3, biological replicates. c AGR2 protein expression level in WT and hnRNPL knockdown MDA-MB-231 cells with or without LINC02273 overexpression by immunoblotting. d ChIP-qPCR was performed in WT and LINC02273 knockout MDA-MB-231 cells overexpressed with hnRNPL or pCDH empty vector with indicated antibodies. Normalized to 1% input. n = 3, biological replicates. e ChIP-qPCR was performed in WT and hnRNPL knockdown (hnRNPL-gRNA38) MDA-MB-231 cells overexpressed with LINC02273 or pCDH empty vector with indicated antibodies. Normalized to 1% input. n = 3, biological replicates. f Correlation analysis of the gene expression profile between hnRNPL and LINC02273. g Correlation analysis of the gene expression profile between AGR2 and LINC02273. For (f-g), RNA expression data from 606-patient cohort were used (Spearman r). h Correlation analysis between AGR2 and LINC02273 in 46 LN samples (Spearman r). i Kaplan-Meier RFS analysis of AGR2 expression in 319-patient cohort (log rank test). j Kaplan-Meier RFS analysis of AGR2 and LINC02273 expression in 319-patient cohort. Cutoff for LINC02273 was same to Fig. 1f (log rank test). For (a-e) means ± s.e.m. are shown, and P values were determined by independent sample t-tests. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant